Patients in the ivonescimab group demonstrated a significantly greater progression-free survival than those in the ...

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous adverse events, including bullous pemphigoid and lipodystrophy.

Although recommended, many patients with metastatic clear cell RCC still don’t receive immune checkpoint inhibitor-based combinations as first-line treatment.

Avelumab is described as a human anti-programmed death ligand-1 (PD-L1) antibody approved for use in multiple tumour types. Aulos say that pre-clinical results detail strong anti-cancer activity ...

Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy ...

In interviews with Targeted Oncology, Ronan J. Kelly, MD, MBA, and David Zhen, MD, discuss the CheckMate 649 trial of ...

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

Oncology nurses can encourage clinical trial enrollment for patients with anaplastic thyroid cancer, a rare and aggressive ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 6.65%, which has investors questioning if this is right time to ...

Small-cell lung cancer represents a highly aggressive neuroendocrine subtype of lung cancer. In distant metastatic or ...